Completed PHASE2 INTERVENTIONAL 3-arm NCT01536938

LEO 90100 in the Treatment of Psoriasis Vulgaris

Sponsor: LEO Pharma

Interventions Betamethasone Calcipotriol LEO 90100

Updated 9 times since 2017 Last updated: Feb 21, 2025 Started: May 31, 2012 Primary completion: Sep 30, 2012 Completion: Nov 30, 2012

This information is for research purposes only and is not medical advice. Consult a healthcare provider before making any medical decision.

Listed as NCT01536938, this PHASE2 trial focuses on Psoriasis Vulgaris and remains completed. Sponsored by LEO Pharma, it has been updated 9 times since 2012, reflecting limited change activity. This study adds to the evidence base for this therapeutic area through structured, versioned documentation.

Status Flow

Change History

9 versions recorded

Apr 2025 — Present [monthly]

Completed PHASE2
Sep 2024 — Apr 2025 [monthly]

Completed PHASE2
Jul 2024 — Sep 2024 [monthly]

Completed PHASE2
Jan 2023 — Jul 2024 [monthly]

Completed PHASE2
Dec 2022 — Jan 2023 [monthly]

Completed PHASE2

▶ Show 4 earlier versions

Jan 2021 — Dec 2022 [monthly]

Completed PHASE2
Jun 2018 — Jan 2021 [monthly]

Completed PHASE2
Feb 2017 — Jun 2018 [monthly]

Completed PHASE2
Jan 2017 — Feb 2017 [monthly]

Completed PHASE2

First recorded

May 2012

Trial started

Per CT.gov start date — pre-dates our first snapshot

Eligibility Summary

No eligibility information available.

Contact Information

Sponsor contact:

LEO Pharma

Data source: LEO Pharma

For direct contact, visit the study record on ClinicalTrials.gov .

Study Locations

Ann Arbor, United States , Arlington Heights, United States , Bay City, United States , Buffalo Grove, United States , Coral Gables, United States , Dallas, United States , Denver, United States , East Windsor, United States , Evansville, United States , Fort Washington, United States and 19 more locations